Disc Medicine company information, Employees & Contact Information

Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP) Yahoo Finance

Disc Medicine Provides Update on Hematology Portfolio and GlobeNewswire

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week Sahm

$616M cash: Disc Medicine submits NDA for bitopertin, CNPV shortens review to 1–2 months Stock Titan

Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

Disc Medicine: Forging Ahead In Hematology (NASDAQ:IRON) Seeking Alpha

1-2 Month Review Window: Disc Medicine Receives FDA CNPV for Bitopertin in EPP; NDA Filed Sept 2025 Stock Titan

Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference Sahm

Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF) GlobeNewswire

Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) Yahoo Finance

Clinical-Stage Biotech Disc Medicine Lines Up Four Major Wall Street Healthcare Conference Appearances Stock Titan

Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress Yahoo Finance

Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Yahoo Finance

Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025 Yahoo Finance

Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) Yahoo Finance

Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting Yahoo Finance

Disc Medicine, Inc. Appoints Nadim Ahmed to Board of Directors Nasdaq

Disc Medicine, Inc. Receives Positive FDA Feedback for Bitopertin NDA Submission in Erythropoietic Protoporphyria Nasdaq

Disc Medicine, Inc. Reports Q1 2025 Financial Results and Updates on Bitopertin and Pipeline Programs Nasdaq

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire

Disc Medicine Highlights Positive Clinical Data for Bitopertin, DISC-0974, and DISC-3405 at EHA 2025; Management to Host Corporate Update Call Nasdaq

A Fresh Look at Disc Medicine’s Valuation After Bitopertin NDA Submission and Positive Phase 2 Data Yahoo Finance

Phase 1b data: Disc Medicine to present DISC-0974 results in NDD-CKD anemia at ASN Nov 8 Stock Titan

Disc Medicine Reveals First Disease-Modifying EPP Treatment Data Among 6 Clinical Updates at EHA 2025 Stock Titan

Disc Medicine Announces Underwritten Offering of Common Stock GlobeNewswire

First Potential Treatment for EPP: Disc Medicine Files FDA Application for Breakthrough Drug Bitopertin Stock Titan

Disc Medicine CFO Joanne Bryce to Retire citybiz

Disc Medicine secures $200m financing to support trials Clinical Trials Arena

With 65% ownership, Disc Medicine, Inc. (NASDAQ:IRON) boasts of strong institutional backing Yahoo Finance

Disc Medicine, Inc. (IRON) Set to Submit NDA for Bitopertin in October 2025 Yahoo Finance

Lessons in Bioreactor Scale-Up, Part 8: Strategies To Control dCO2 Accumulation Using Aeration Flow Rate BioProcess International

Phase 2 AURORA Trial Demonstrates Clinical Activity of Bitopertin for EPP HCPLive

Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting PR Newswire

Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria PR Newswire

Disc Medicine: Potential Promise Amid Uncertainty (NASDAQ:IRON) Seeking Alpha

MWTX-003 Wins FDA Fast Track Designation for Polycythemia Vera OncLive

Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases PR Newswire

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress (IRON) Seeking Alpha

Disc Medicine Initiates Phase 1 Clinical Study of DISC-0974, a First-In-Class Inhibitor of Hemojuvelin (HJV) in Development for the Treatment of Anemia of Inflammation PR Newswire

Disc Medicine Expands Hematology Pipeline with Worldwide Licensing Agreement for Bitopertin, a First-in-Class Modulator of Heme Synthesis PR Newswire

Disc Medicine nabs $90M for blood disease pipeline, new Roche asset Fierce Biotech